Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink

Core Insights - Idorsia Ltd has entered into an exclusive distribution and commercialization agreement with Pharmalink Drug Store L.L.C for QUVIVIQ (daridorexant) in the UAE, Kuwait, Qatar, Oman, and Bahrain [2][4] - QUVIVIQ is an innovative treatment for insomnia that has shown improvement in daytime functioning and addresses the unmet need for safer alternatives to traditional insomnia medications [3][5][6] Company Overview - Idorsia is focused on developing transformative medicines and aims to evolve into a leading biopharmaceutical company with a strong scientific core [16][17] - The company is headquartered in Allschwil, Switzerland, and is listed on the SIX Swiss Exchange [18] Product Details - QUVIVIQ is a dual orexin receptor antagonist that selectively targets the orexin system, promoting restorative sleep without broadly suppressing brain activity [6] - Clinical trials have demonstrated that daridorexant significantly improves sleep onset, maintenance, and total sleep time at doses of 25mg and 50mg compared to placebo, with a notable improvement in daytime functioning at the 50mg dose [7] Market Context - Insomnia is highly prevalent in the Gulf Cooperation Council (GCC) region, creating a significant market opportunity for QUVIVIQ [4] - The collaboration with Pharmalink enhances Idorsia's commitment to establishing QUVIVIQ as a global brand, complementing its existing partnerships in various regions including the US, Canada, and Europe [8]